Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 3/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5412784 | 0.98 | HPGD (0.62) | HPGDTSHRDPP4PDE4APDE4B | |
| Hydrochloric Acid SCHEMBL6872103 | 0.98 | HPGD (0.62) | HPGDTSHRDPP4PDE4APDE4B | |
| SCHEMBL9621553 | 0.83 | HTT (0.62) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 | |
| SCHEMBL25231697 | 0.83 | DPP4 (0.53) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 | |
| SCHEMBL2222168 | 0.83 | HPGD (0.53) | HPGDTSHRDPP4PDE4APDE4B | |
| SCHEMBL2223753 | 0.83 | DPP4 (0.53) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 | |
| SCHEMBL25237209 | 0.83 | DPP4 (0.53) | HPGDTSHRDPP4SMN1; SMN2ALDH1A1 | |
| SCHEMBL2814838 | 0.83 | PRMT6 (0.46) | HPGDTSHRDPP4PDE4APDE4B | |
| SCHEMBL6128482 | 0.81 | L3MBTL1 (0.56) | HPGDTSHRDPP4ALDH1A1L3MBTL1 | |
| Nebracetam SCHEMBL195354 | 0.80 | HPGD (0.60) | HPGDTSHRDPP4PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2015161011-A1 | BENZAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-0163260-A1 | Novel substituted pyrrolidinones, process for their manufacture and pharmaceutics | BOEHRINGER INGELHEIM KG (DE) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HPGD 2976/4885TSHR 3605/4885DPP4 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.